These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 33576301)

  • 1. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
    Filippi R; Depetris I; Satolli MA
    Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
    [No Abstract]   [Full Text] [Related]  

  • 2. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
    Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
    Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N; McDermott R
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
    BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
    Hong DS; Bauer TM; Lee JJ; Dowlati A; Brose MS; Farago AF; Taylor M; Shaw AT; Montez S; Meric-Bernstam F; Smith S; Tuch BB; Ebata K; Cruickshank S; Cox MC; Burris HA; Doebele RC
    Ann Oncol; 2019 Feb; 30(2):325-331. PubMed ID: 30624546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Larotrectinib for the treatment of TRK fusion solid tumors.
    Laetsch TW; Hawkins DS
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734
    [No Abstract]   [Full Text] [Related]  

  • 8. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
    Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
    Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
    Blauel ER; Laetsch TW
    Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Larotrectinib: First Global Approval.
    Scott LJ
    Drugs; 2019 Feb; 79(2):201-206. PubMed ID: 30635837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF; Demetri GD
    Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F; Rudzinski ER; Sepulveda AR
    J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E; Scaltriti M; Drilon A
    Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRK Inhibitors: Clinical Development of Larotrectinib.
    Bhangoo MS; Sigal D
    Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib.
    Rudzinski ER; Hechtman J; Roy-Chowdhuri S; Rudolph M; Lockwood CM; Silvertown J; Wierzbinska J; Shen K; Norenberg R; Nogai H; Hong DS; Drilon A; Laetsch TW
    Cancer Genet; 2022 Jan; 260-261():46-52. PubMed ID: 34929613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Larotrectinib: A Targeted Therapy for Solid Tumors.
    Mota-George G; Schneider SM
    Clin J Oncol Nurs; 2021 Apr; 25(2):181-187. PubMed ID: 33739345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.
    Lim KHT; Kong HL; Chang KTE; Tan DSW; Tan IBH; Mohamad F; Soh SY; Pang BN; Soo RA; Choo SP; Hsieh WS; Aung L
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):394-403. PubMed ID: 34806337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
    DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
    Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.
    Carlson JJ; Italiano A; Brose MS; Federman N; Lassen U; Kummar S; Sullivan SD
    Am J Manag Care; 2022 Jan; 28(2 Suppl):S26-S32. PubMed ID: 35201681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.